WESTLAKE VILLAGE, Calif. — August 19, 2025 — Leads & Copy — Angitia Biopharmaceuticals will present data from its AGA2115 program for osteogenesis imperfecta (OI) at the American Society for Bone and Mineral Research 2025 Annual Meeting (ASBMR) from Sept. 5-8 in Seattle, WA. Conference organizers selected preclinical and clinical abstracts for AGA2115 (or surrogate rodent antibody) submitted by the company as highlights of the annual meeting, two of which were selected for oral presentations.
One oral presentation will be titled, “AGA2115, a Bispecific Antibody Neutralizing DKK1 and Sclerostin, Increased Bone Formation, Decreased Bone Resorption, and Led to Significant BMD Gains in a First-in-Human, Single- and Multiple-dose, Placebo-Controlled Randomized Study,” with Eric Orwoll, M.D., presenting on Saturday, Sept. 6, from 11:15 a.m. – 12:30 p.m. The other presentation is titled: “AGA2115, a Bispecific Antibody Neutralizing Both Dickkopf-1 (DKK1) and Sclerostin Increased Bone Formation and Decreased Bone Resorption Resulting in Significant Gains in Bone Mass and Strength in Nonhuman Primates (NHPs),” to be presented by Ann Zovein, M.D. on Sunday, Sept. 7, from 3:45 – 5:00 p.m.
Three abstracts will be presented as posters, along with one additional poster presentation from a collaborator, the Willie Laboratory at the Shriners Hospital for Children, Research Center. The Willie Laboratory will also host a poster preview talk at the conference on September 4, the day prior to the meeting.
Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with pathophysiology driven by abnormal collagen metabolism resulting in skeletal deformity, bone fragility, reduced bone mass, and variable extra-skeletal symptoms. OI occurs in approximately 1 in 15,000 births, with between 20,000 to 50,000 affected individuals in the United States. There are no approved therapies for the treatment of OI.
AGA2115 is a first-in-class, bispecific antibody being developed for the treatment of osteogenesis imperfecta. A Phase 2 study is planned to evaluate the efficacy of AGA2115 in adult OI patients, with additional studies in pediatric patients to follow.
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Contact: William Windham, Solebury Strategic Communications, wwindham@soleburystrat.com, 646-378-2946
Source: Angitia Biopharmaceuticals
